Drugs for the Brain from the Brain
We have developed a targeted glycosylation platform that enables precise control over peptide delivery across the blood-brain barrier, offering a novel approach to treating neurological disorders ranging from stroke to neurodegenerative diseases.
The Problem
Each year, approximately 795,000 Americans experience a stroke, with about 610,000 being first-time events. Stroke remains a leading cause of death and long-term disability, and while rates are declining among older adults, incidence is rising in younger populations (ages 18–49). Successful recovery depends on effectively modulating inflammatory processes and promoting neural repair. However, current therapies are limited by their inability to deliver active compounds across the blood-brain barrier (BBB)—particularly during the critical mid-term rehabilitation phase.
The Solution
Teleport Pharmaceuticals leverages endogenous neurotransmitters as the foundation for its innovative glycopeptide therapeutics, designed to treat a broad spectrum of degenerative neurological disorders. Our initial focuses are stroke and traumatic brain injury, but animal studies support potential in neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and ALS (Lou Gehrig’s disease).
Our glycosylation platform enables the delivery and modulation of DMPK parameters including BBB penetration to achieve required and desired distribution and residence profiles.
The Opportunity
The current US stroke market is estimated around $14B with a CAGR of about 8%. This market requires sub-chronic treatment regimens with a significant impact on the long-term quality of life for patients. The neurodegeneration market is valued upwards of $50B with a CAGR of 5.5%. Both market are in need of disease modifying treatments.
Committed to advancing the future of medicine, Teleport Pharmaceuticals is pioneering novel peptide-based drug design to deliver transformative treatments for patients worldwide.
Status
The lead compound has shown potential in multiple disease relevant animal models showing significant behavioral and histological improvements. The compounds are well tolerated and have shown no significant adverse effects. Synthesis and preparation protocols are well established and should enable progression into preclinical investigation.
Meet the Team
Kevin Scott PhD
College of Science
Teleport Team
Peter Nestler PhD
Tech Launch Arizona
Contact us today.
Check out more Pharma startups.
View All Startups & Inventions
We have developed a targeted glycosylation platform that enables precise control over peptide delivery across the blood-brain barrier, offering a novel approach to treating neurological disorders ranging from stroke to neurodegenerative diseases.
